Valuation: Northwest Biotherapeutics, Inc.

Market Cap 307M 269M 248M 232M 436M 29.01B 446M 2.98B 1.15B 14.31B 1.15B 1.13B 49.68B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 403M 353M 326M 304M 572M 38.09B 586M 3.92B 1.51B 18.79B 1.51B 1.48B 65.24B EV / Sales 2026 *
-
EV / Sales 2027 * 11.1x
Free-Float
95.04%
Yield 2026 *
-
Yield 2027 * -
05-15 Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-21 Northwest Biotherapeutics Establishes Dedicated Leukapheresis Clinic CI
04-15 Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
04-14 Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt CI
11-14 Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
11-13 Northwest Biotherapeutics, Inc. announced that it expects to receive $4.75 million in funding from Yorkville Advisors Global LP CI
31/10/25 Northwest Biotherapeutics, Inc. Enters into A Commercial Loan Agreement and Note with Streeterville Capital, LLC CI
26/10/25 Northwest Biotherapeutics, Inc. announced that it has received $5.505 million in funding CI
23/10/25 Northwest Biotherapeutics, Inc. completed the acquisition of Advent Bioservices Ltd from Toucan Holdings LLC. CI
26/08/25 Northwest Biotherapeutics, Inc. entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million. CI
18/08/25 Northwest Biotherapeutics, Inc. Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman CI
14/08/25 Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
29/06/25 Northwest Biotherapeutics, Inc. announced that it expects to receive $2.85 million in funding from Yorkville Advisors Global LP CI
1 day+0.54%
1 week-2.21%
Current month-17.88%
1 month-15.68%
3 months-5.82%
6 months-18.24%
Current year-18.71%
1 week 0.18
Extreme 0.18
0.24
1 month 0.18
Extreme 0.18
0.24
Current year 0.18
Extreme 0.18
0.34
1 year 0.18
Extreme 0.18
0.37
3 years 0.17
Extreme 0.1685
1.09
5 years 0.17
Extreme 0.1685
2.05
10 years 0.14
Extreme 0.14
2.51
Manager TitleAgeSince
Chief Executive Officer 82 31/05/2007
Chief Executive Officer 71 07/06/2011
Chief Tech/Sci/R&D Officer 67 31/12/1999
Director TitleAgeSince
Director/Board Member 82 31/12/1997
Chairman 71 16/05/2007
Director/Board Member 57 31/03/2012
Date Insider Type Main position Quantity % Market Cap.
28/08/24Don

Founder

1,000,000 0.0826%
08/08/24Don

Chief Technology Officer

3,000,000 0.2478%
07/08/24Don

Founder

1,000,000 0.0826%
Change 5-day change 1-year change 3-year change Capi.($)
+0.54%-2.21%-22.47%-67.25% 307M
+1.83%-1.65%+70.20%+124.99% 55.78B
+6.76%+18.10%+91.66%+104.09% 55.66B
-0.30%+3.66%-11.77%-12.97% 23.84B
+1.01%+3.45%+5.00%+400.81% 22.7B
+4.28%+5.91%+37.60%-29.86% 16.12B
+0.10%+5.75%+23.18%+184.09% 13.64B
+9.96%+15.98%+157.65%+310.89% 14.8B
+0.93%+4.10%+76.61%+131.39% 12.16B
-1.05%+8.31%+162.29%+165.67% 11.85B
Average +2.41%+6.31%+59.00%+131.18% 22.69B
Weighted average by Cap. +3.14%+7.69%+65.91%+139.85%

Financials

2026 *2027 *
Net sales - 38.93M 34.09M 31.47M 29.39M 55.32M 3.68B 56.58M 379M 146M 1.82B 146M 143M 6.3B
Net income - -
Net Debt 96.08M 84.13M 77.66M 72.52M 137M 9.08B 140M 935M 361M 4.48B 361M 353M 15.56B 125M 109M 101M 94.31M 178M 11.81B 182M 1.22B 469M 5.83B 469M 459M 20.23B
Logo Northwest Biotherapeutics, Inc.
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, Northwest Biotherapeutics Capital Limited, Northwest Biotherapeutics B.V., Advent BioServices Ltd., and others.
Employees
105
Date Price Change Volume
30/06/26 US$0.1860 +0.54% 350,636
29/06/26 US$0.1850 -4.59% 7,103,920
26/06/26 US$0.1939 +4.27% 5,291,119
25/06/26 US$0.1860 -1.66% 3,237,943
24/06/26 US$0.1891 -0.58% 1,796,624
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.1850USD
Average target price
1.000USD
Spread / Average Target
+440.54%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NWBO Stock